Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
55 hedge funds and large institutions have $104M invested in Oncternal Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
31% more funds holding
Funds holding: 42 → 55 (+13)
15% more capital invested
Capital invested by funds: $90.6M → $104M (+$13.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$27.2M |
| 2 |
BlackRock
New York
|
+$3.99M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$3.28M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.07M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$5.07M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.05M |
| 3 |
Millennium Management
New York
|
-$1.83M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.12M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$886K |
ONCT Hedge Fund Activity: Q2 2018 in Review
55 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2018, worth a combined $104M — up 15% from $90.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ONCT positions and 8 closed out — a net gain of 13 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $27.2M. The largest seller was Boxer Capital, cutting an estimated $5.07M.
- 55 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2018, up from 42 in Q1 2018.
- Funds reported $104M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2018, up 15% quarter-over-quarter.
- 21 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2018 and 8 closed out, a net change of +13 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2018 was Perceptive Advisors, an estimated $27.2M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2018 was Boxer Capital, an estimated $5.07M sold.
Based on aggregated 13F filings for Q2 2018.